Streetbeat News

Analyst Ratings

CYTK

Morgan Stanley analyst Jeffrey Hung has reiterated an Overweight rating on Cytokinetics (NASDAQ:CYTK) and maintained a $60 price target.

Portfolio Pulse from Benzinga Newsdesk

August 04, 2023 | 4:54 pm

MRNA

B of A Securities analyst Geoff Meacham maintains a Neutral rating on Moderna (NASDAQ:MRNA) and lowers the price target from $175 to $150.

Portfolio Pulse from jenniferd'souza@benzinga.com

August 04, 2023 | 4:54 pm

COMM

Morgan Stanley analyst Meta Marshall has maintained an Equal-Weight rating on CommScope Hldg Co (NASDAQ:COMM) and lowered the price target from $6 to $4.5.

Portfolio Pulse from Benzinga Newsdesk

August 04, 2023 | 4:53 pm

INZY

HC Wainwright & Co. analyst Edward White maintains a 'Buy' rating on Inozyme Pharma (NASDAQ:INZY) but lowers the price target from $19 to $16.

Portfolio Pulse from Benzinga Newsdesk

August 04, 2023 | 4:52 pm

AAPL

Canaccord Genuity analyst Michael Walkley maintains a 'Buy' rating on Apple (NASDAQ:AAPL) and raises the price target from $185 to $205.

Portfolio Pulse from jenniferd'souza@benzinga.com

August 04, 2023 | 4:52 pm

GXO

Susquehanna analyst Bascome Majors maintains a positive outlook on GXO Logistics (NYSE:GXO) and raises the price target from $73 to $76.

Portfolio Pulse from richadhand@benzinga.com

August 04, 2023 | 4:51 pm

PLNT

B of A Securities analyst Rafe Jadrosich maintains a Buy rating on Planet Fitness (NYSE:PLNT) but lowers the price target from $95 to $80.

Portfolio Pulse from jenniferd'souza@benzinga.com

August 04, 2023 | 4:51 pm

GFS

Susquehanna analyst Mehdi Hosseini has maintained a positive rating on GLOBALFOUNDRIES (NASDAQ:GFS) but lowered the price target from $84 to $82.

Portfolio Pulse from richadhand@benzinga.com

August 04, 2023 | 4:50 pm

CLVT

Morgan Stanley analyst Toni Kaplan has maintained an Equal-Weight rating on Clarivate (NYSE:CLVT) and lowered the price target from $11 to $9.

Portfolio Pulse from Benzinga Newsdesk

August 04, 2023 | 4:50 pm

CRUS

Susquehanna analyst Christopher Rolland maintains a positive outlook on Cirrus Logic (NASDAQ:CRUS) and raises the price target from $90 to $95.

Portfolio Pulse from richadhand@benzinga.com

August 04, 2023 | 4:50 pm